Management of psychotropic medications in adults with intellectual disability: a scoping review

References

• Schalock RL, Luckasson R, Tasse MJ. Intellectual disability: definition, classification, and systems of supports. 12th ed. Silver Spring, Maryland: American Association on Intellectual and Developmental Disabilities; 2021.
   Google Scholar
• Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. 2015;59(1):11–25.
   PubMed Web of Science ®Google Scholar
• Marshall T. Audit of the use of psychotropic medication for challenging behaviour in a community learning disability service. Psychiatr Bull. 2004;28(12):447–450.
   Google Scholar
• Health Service Executive Disability Services Community Operations: Medicines Management Steering Group. National framework for medicines management in disability services. Dublin: HSE; 2018 [cited 2022 May 8]. Available from: http://hdl.handle.net/10147/629055
   Google Scholar
• Public Health England. Prescribing of psychotropic drugs to people with learning disabilities and/or autism by general practitioners in England. London: Public Health England; 2015.
   Google Scholar
• Department of Health. Transforming care: a national response to winterbourne view hospital. Department of Health Review: Final report. London: Department of Health; 2012.
   Google Scholar
• O’Dwyer C, McCallion P, Henman M, et al. Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities. J Appl Res Intellect Disabil. 2019;32(4):981–993.
   PubMed Web of Science ®Google Scholar
• Sheehan R, Hassiotis A, Walters K, et al. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. Br Med J. 2015;351:h4326.
   PubMed Web of Science ®Google Scholar
• Cooper SA, Melville CA, Einfeld SL. Psychiatric diagnosis, intellectual disabilities and diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC‐LD). J Intellect Disabil Res. 2003;47:3–15.
   PubMed Web of Science ®Google Scholar
• Royal College of Psychiatrists. ‘Challenging behaviour: a unified approach – update’, clinical and service guidelines for supporting people with learning disabilities who are at risk of receiving abusive or restrictive practices; 2016. Available from: https://www.england.nhs.uk/6cs/wp-content/uploads/sites/25/2016/07/challeng-behvr-unified-apprch.pdf.
   Google Scholar
• de Leon J, Greenlee B, Barber J, et al. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30(4):613–669.
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–615.
   PubMed Web of Science ®Google Scholar
• Bhaumik S, Branford D. The frith prescribing guidelines: for adults with intellectual disability. Aberdeen: HealthComm; 2008.
   Google Scholar
• Branford D, Gerrard D, Saleem N, et al. Stopping over-medication of people with intellectual disability, autism or both (STOMP) in England part 1–history and background of STOMP. AMHID. 2019;13(1):31–40.
   Google Scholar
• Tanwar M, Lloyd B, Julies P. Challenging behaviour and learning disabilities: prevention and interventions for children with learning disabilities whose behaviour challenges: NICE guideline 2015. Arch Dis Child Educ Pract Ed. 2017;102(1):24–27.
   PubMed Web of Science ®Google Scholar
• Deb S, Unwin GL. Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature. Curr Opin Psychiatry. 2007;20(5):461–6466.
   PubMed Web of Science ®Google Scholar
• Sheehan R, Hassiotis A. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Lancet Psychiatry. 2017;4(3):238–256.
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
   Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473.
   PubMed Web of Science ®Google Scholar
• Costello A, Hehir C, Sharma D, et al. Management of psychotropic medications in adults with intellectual disability: a scoping review protocol. HRB Open Res. 2021;4:30.
   PubMedGoogle Scholar
• Levac D, Colquhoun H, O'Brien K. Scoping studies: advancing the methodology. Implement Sci. 2010;5(69):69.
   PubMed Web of Science ®Google Scholar
• Peters MD, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–2126.
   PubMedGoogle Scholar
• Bradbury-Jones C, Aveyard H, Herber OR, et al. Scoping reviews: the PAGER framework for improving the quality of reporting. Int J Soc Res Methodol. 2022;25:457–470.
   Web of Science ®Google Scholar
• Westphaln KK, Regoeczi W, Masotya M, et al. From Arksey and O’Malley and beyond: customizations to enhance a team-based, mixed approach to scoping review methodology. MethodsX. 2021;8:101375.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Branford D. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. J Intellect Disabil Res. 1996;40(4):358–368.
   PubMedGoogle Scholar
• Bowring DL, Totsika V, Hastings RP, et al. Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. J Intellect Disabil Res. 2017;61(6):604–617.
   PubMed Web of Science ®Google Scholar
• de Kuijper GM, Hoekstra PJ. Physicians’ reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability. J Intellect Disabil Res. 2017;61(10):899–908.
   PubMed Web of Science ®Google Scholar
• Erickson SR. In-home comprehensive medication reviews for adults with intellectual or developmental disability: a pilot study. J Am Pharm Assoc. 2020;60(6):e279–e291.
   Google Scholar
• Espadas C, Ballester P, Londoño AC, et al. Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability. Psychiatry Res. 2020;292:113321.
   PubMed Web of Science ®Google Scholar
• Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil. 2004;25(6):509–521.
   PubMed Web of Science ®Google Scholar
• Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol. 1993;13(6):448–451.
   PubMed Web of Science ®Google Scholar
• Niven A, Goodey R, Webb A, et al. The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach. Br J Learn Disabil. 2018;46(1):4–9.
   Web of Science ®Google Scholar
• Perry BI, Cooray SE, Mendis J, et al. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. J Intellect Disabil Res. 2018;62(2):140–149.
   PubMed Web of Science ®Google Scholar
• Sachdev P. Drug-induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors. Aust N Z J Psychiatry. 1992;26(2):242–248.
   PubMed Web of Science ®Google Scholar
• Song M, Ware R, Doan T, et al. Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study. J Intellect Disabil Res. 2020;64(1):45–56.
   PubMed Web of Science ®Google Scholar
• Tan X, Marshall VD, Balkrishnan R, et al. Psychotropic medication adherence among community-based individuals with developmental disabilities and mental illness. J Ment Health Res Intellect Disabil. 2015;8(1):1–22.
   Web of Science ®Google Scholar
• Tsakanikos E, Costello H, Holt G, et al. Behaviour management problems as predictors of psychotropic medication and use of psychiatric services in adults with autism. J Autism Dev Disord. 2007;37(6):1080–1085.
   PubMed Web of Science ®Google Scholar
• Bradley E, Cheetham T. The use of psychotropic medication for the management of problem behaviours in adults with intellectual disabilities living in Canada. Adv Mental Hlth Intell Disabil. 2010;4(3):12–26.
   Google Scholar
• Kleijwegt B, Pruijssers A, de Jong-Bakker L, et al. Support staff’s perceptions of discontinuing antipsychotics in people with intellectual disabilities in residential care: a mixed-method study. J Appl Res Intellect Disabil. 2019;32(4):861–870.
   PubMed Web of Science ®Google Scholar
• Aman MG, Singh NN. A critical appraisal of recent drug research in mental retardation: the coldwater studies. J Ment Defic Res. 2008;30(3):203–216.
   Google Scholar
• Hässler F, Glaser T, Beneke M, et al. Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study. Br J Psychiatry. 2007;190:447–448.
   PubMed Web of Science ®Google Scholar
• Patel NC, Crismon ML, Rush AJ, et al. Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders. Am J Health Syst Pharm. 2001;58(19):1824–1829.
   PubMed Web of Science ®Google Scholar
• Ramerman L, de Kuijper G, Scheers T, et al. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study. J Intellect Disabil Res. 2019;63(5):418–428.
   PubMed Web of Science ®Google Scholar
• Drmic S, Franic T. Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability–a case series. Coll Antropol. 2008;32(2):325–330.
   PubMedGoogle Scholar
• Janowsky DS, Barnhill LJ, Shetty M, et al. Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. J Clin Psychopharmacol. 2005;25(1):19–25.
   PubMed Web of Science ®Google Scholar
• Ruedrich S, Swales TP, Fossaceca C, et al. Effect of divalproex sodium on aggression and self-injurious behaviour in adults with intellectual disability: a retrospective review. J Intellect Disabil Res. 1999;43(2):105–111.
   PubMedGoogle Scholar
• Ruedrich SL, Swales TP, Rossvanes C, et al. Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. J Intellect Disabil Res. 2008;52(Pt 2):132–140.
   PubMedGoogle Scholar
• Troisi A, Vicario E, Nuccetelli F, et al. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry. 1995;28(3):73–76.
   PubMed Web of Science ®Google Scholar
• Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet. 2008;371(9606):57–63.
   PubMed Web of Science ®Google Scholar
• Schwarz V, Reis O, Glaser T, et al. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Pharmacopsychiatry. 2014;47(1):29–32.
   PubMed Web of Science ®Google Scholar
• Hässler F, Glaser T, Reis O. Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation–a 2-year follow-up on a withdrawal study. Pharmacopsychiatry. 2011;44(7):339–343.
   PubMed Web of Science ®Google Scholar
• Ji NY, Findling RL. Pharmacotherapy for mental health problems in people with intellectual disability. Curr Opin Psychiatry. 2016;29(2):103–125.
   PubMed Web of Science ®Google Scholar
• Sohanpal S, Deb S, Thomas C, et al. The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. J Intellect Disabil Res. 2007;51(Pt 10):750–765.
   PubMedGoogle Scholar
• Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27(3):309–336.
   PubMed Web of Science ®Google Scholar
• O’Dwyer M, Meštrović A, Henman M. Pharmacists’ medicines-related interventions for people with intellectual disabilities: a narrative review. Int J Clin Pharm. 2015;37(4):566–578.
   PubMed Web of Science ®Google Scholar
• Ramerman L, Hoekstra PJ, de Kuijper G. Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability. J Appl Res Intellect Disabil. 2018;31(6):1062–1070.
   PubMed Web of Science ®Google Scholar
• Rasaratnam R, Crouch K, Regan A. Attitude to medication of parents/primary carers of people with intellectual disability. J Intellect Disabil Res. 2004;48(Pt 8):754–763.
   PubMedGoogle Scholar
• Sheehan R, Hassiotis A, Strydom A, et al. Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK. BMJ Open. 2019;9(11):e032861.
   PubMed Web of Science ®Google Scholar
• Shankar R, Wilcock M, Deb S, et al. A structured programme to withdraw antipsychotics among adults with intellectual disabilities: the Cornwall experience. J Appl Res Intellect Disabil. 2019;32(6):1389–1400.
   PubMed Web of Science ®Google Scholar
• Sheehan R, Strydom A, Marston L, et al. A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. BMJ Open. 2019;9(12):e033827.
   PubMed Web of Science ®Google Scholar
• Royal College of Psychiatrists. Psychotropic drug prescribing for people with intellectual disability, mental health problems and/or behaviours that challenge: practice guidelines. Faculty report FR/ID/09. London: Royal College of Psychiatrists; 2016.
   Google Scholar
• Eady N, Courtenay K, Strydom A. Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability. Drugs Aging. 2015;32(2):95–102.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry. 2000;176:42–46.
   PubMed Web of Science ®Google Scholar
• Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. J Intellect Disabil Res. 1996;40(4):322–329.
   PubMedGoogle Scholar
• de Kuijper G, Mulder H, Evenhuis H, et al. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. J Clin Psychopharmacol. 2013;33(4):520–524.
   PubMed Web of Science ®Google Scholar
• Hanzel TE, Bauernfeind JD, Kalachnik JE, et al. Results of barbiturate antiepileptic drug discontinuation on antipsychotic medication dose in individuals with intellectual disability. J Intellect Disabil Res. 2001;44(2):155–163.
   Google Scholar
• Hässler F, Glaser T, Pap A, et al. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation – secondary parameter analyses. Pharmacopsychiatry. 2008;41(6):232–239.
   PubMed Web of Science ®Google Scholar
• Janowsky DS, Barnhill LJ, Khalid AS, et al. Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. J Clin Psychopharmacol. 2008;28(4):401–405.
   PubMed Web of Science ®Google Scholar
• Radouco-Thomas M, Bolduc M, Brisson A, et al. Pilot study on the use of psychotropic medication in persons with mental retardation. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):879–883.
   PubMed Web of Science ®Google Scholar
• Smith C, Felce D, Ahmed Z, et al. Sedation effects on responsiveness: evaluating the reduction of antipsychotic medication in people with intellectual disability using a conditional probability approach. J Intellect Disabil Res. 2002;46(Pt 6):464–471.
   PubMedGoogle Scholar
• Valdovinos MG, Henninger-McMahon M, Schieber E, et al. Assessing the impact of psychotropic medication changes on challenging behavior of individuals with intellectual disabilities. Int J Dev Disabil. 2016;62(3):200–211.
   PubMed Web of Science ®Google Scholar
• Zaal RJ, Ebbers S, Borms M, et al. Medication review using a systematic tool to reduce inappropriate prescribing (STRIP) in adults with an intellectual disability: a pilot study. Res Dev Disabil. 2016;55:132–142.
   PubMed Web of Science ®Google Scholar
• Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):1–4.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–179.
   PubMed Web of Science ®Google Scholar
• de Kuijper G, Hoekstra P, Visser F, et al. Use of antipsychotic drugs in individuals with intellectual disability (ID) in The Netherlands: prevalence and reasons for prescription. J Intellect Disabil Res. 2010;54(7):659–667.
   PubMedGoogle Scholar
• Bird F, Harper JM, Luiselli JK, et al. Psychotropic medication monitoring in a human services organization for children with autism spectrum disorder: description and evaluation of interdisciplinary team review. Behav Anal Pract. 2022:1–11. https://doi.org/10.1007/s40617-022-00699-4
   Google Scholar
• Oudshoorn CE, Frielink N, Nijs SL, et al. eHealth in the support of people with mild intellectual disability in daily life: a systematic review. J Appl Res Intellect Disabil. 2020;33(6):1166–1187.
   PubMed Web of Science ®Google Scholar
• United Nations. Convention on the rights of people with disabilities. United Nations; 2006. Available from: https://www.un.org/development/desa/disabilities/convention-on-the-rights-of-persons-with-disabilities.html
   Google Scholar
• Bayliss EA, Shetterly SM, Drace ML, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. JAMA Intern Med. 2022;182(5):534.
   PubMed Web of Science ®Google Scholar
• O'Dwyer M, McCallion P, McCarron M, et al. Measuring drug burden in older adults with intellectual disabilities: Critical issues for consideration in finding the optimal measure to improve safety of medicines use. Expert Opin Drug Saf. 2020;19(6):649–652. doi:10.1080/14740338.2020.1751119. 32241202
   PubMed Web of Science ®Google Scholar
• World Health Organisation. ATC classification index with DDDs. Collaborating Centre for Drug Statistics Methodology. WHO; 1990. Available from: https://www.who.int/tools/atc-ddd-toolkit/methodology
   Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, et al. Tools for assessment of the appropriateness of prescribing and association with patient-related outcomes: a systematic review. Drugs Aging. 2018;35(1):43–60.
   PubMed Web of Science ®Google Scholar
• Pollock A, Campbell P, Struthers C, et al. Development of the ACTIVE framework to describe stakeholder involvement in systematic reviews. J Health Serv Res Policy. 2019;24(4):245–255.
   PubMed Web of Science ®Google Scholar